Skip to main content
. Author manuscript; available in PMC: 2021 Jan 4.
Published in final edited form as: J Clin Immunol. 2015 Oct 9;35(7):661–667. doi: 10.1007/s10875-015-0203-z

Fig. 3.

Fig. 3

Tofacitinib treatment reduces serum soluble Fas ligand (sFasL) levels in MRL/lpr mice. Ten-week old mice (n=5, for each group) were either sham treated with formulation vehicle or tofacitinib for a period of 42 days. The serum sFasL levels were measured when they reached 7 months of age using a commercial ELISA kit from R&D systems (Minneapolis, MN) according to the manufacturer’s instructions